摘要
应用吗啡控释片（ＣＲＭＳ）对晚期癌症伴有中、重度疼痛患者进行镇痛效果和安全性考察。试验组ＣＲＭＳ３０ｍｇｑ１２ｈＰｏ，２５例。对照组硫酸吗啡普通片ＩＲＭＳ１０ｍｇｑ４ｈＰｏ，３１例。均连续服用６天，采用总疼痛强度差、总疼痛缓解度、总镇痛分为镇痛指标，结果表明ＣＲＭＳ和ＩＲＭＳ的镇痛效果无显著性差异。ＣＲＭＳ的主要不良反应如头晕、恶心、呕吐发生率与ＩＲＭＳ无显著性差异。Ｐ＜０．０１，ＣＲＭＳＶＳＩＲＭＳ但前者减少了服药次数。４．２ＣＲＭＳ与ＩＲＭＳ常规给药后，一般在２～３天可达到有效稳定镇痛状态（见表６）。４．３ＣＲＭＳ与ＩＲＭＳ在试验中，均未发现呼吸抑制及血压降低，对心、肝、肾功能未见明显损害。ＣＲＭＳ的毒副作用主要表现恶心、呕吐，发生率第１天达４６．２％和２０．８％，以后逐日下降。分析认为与起始剂量稍高有关外还可能与黄种人对吗啡的敏感性有关。华人表现了明显的胃肠道反应［１］。４．４本试验组５３人连续服药６天表明其耐受性不是主要问题。
With the purpose to observe the efficacy and safety of CRMS in late cancer patients with severe or moderate pain 56 patients were divided into two groups.The test group consisted of 25 cases to whom CRMS 30 mg,q12h po was administered for 6 days. In the control group there were 31 cases who were administered IRMS 10 mg q4h po for 6 days. The observation criteria for pain relief included difference of sum of pain intensity,total pain relief and total analgesic score.The results suggested that there were no significant differences between the two groups for pain relief nor the incidence of side effects such as dizziness,nausea and vomiting.
出处
《中国肿瘤临床》
CAS
CSCD
北大核心
1996年第5期344-347,共4页
Chinese Journal of Clinical Oncology
关键词
疼痛
癌性疼痛
吗啡控释片
硫酸吗啡片
止痛
Carcinomatous pain Controlled relese morphine sulphate Incontrollable release morphine sulphate(IRMS)
